Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
Heated committee debate over Prescription Drug Affordability Board; SB 271 advanced to Finance
Loading...
Summary
SB 271 would create a Prescription Drug Affordability Board to set upper payer payment limits tied to Medicare-negotiated prices for an initial list of drugs; proponents said it would expand negotiated Medicare savings to Virginians, while industry and some patient groups warned of limited evidence of PDAB effectiveness and potential access disruption. The committee voted to report and refer the bill to Finance.
Senator Deeds presented SB 271 (the Affordable Medicine Act), proposing a Prescription Drug Affordability Board that could set upper payer payment limits for certain high-cost drugs. The sponsor outlined an initial implementation that would extend Medicare-negotiated prices for an initial group of drugs to Virginians beginning in 2027–2028 and would exempt drugs treating exclusively rare diseases.
Supporters—AARP, many patient groups and local governments—argued the board would bring near-term savings by adopting negotiated Medicare maximum fair prices for a small initial set of drugs and provide a public, evidence-based review process for affordability. "Drugs don't work if patients can't afford them," said Laura Packard, a cancer survivor and patient advocate who testified online.
Opponents—pharmaceutical companies, biotechnology associations, some patient groups and business organizations—argued the PDAB model has an inconsistent track record in other states and warned that setting upper payer payment limits could not guarantee savings for patients at the pharmacy counter, might chill industry investment and could create access risks for certain therapies. Industry representatives cited experiences in other states and urged alternative reforms (rebate pass-through, PBM accountability) rather than price-setting by a state board.
Committee action: After extended public-comment testimony and questions, the committee adopted a motion to report the bill and re-refer SB 271 to the Finance committee for fiscal analysis. Multiple members said they welcomed additional study but supported advancing the bill for a Finance review of budgetary and access implications.
Next steps: Finance will examine fiscal impacts, implementation mechanics and potential access concerns; sponsors and stakeholders will continue negotiations about exclusions and guardrails for rare-disease medications.
